NAD+ and Aging: Why It Declines 50% by Age 50 — and the Science of Restoring It

NAD+ Biology — Redox Chemistry, the Krebs Cycle, and Why It Is Called the Master Regulator

NAD+ — nicotinamide adenine dinucleotide in its oxidized form — exists in a continuous cycle with its reduced partner NADH. This interconversion is the metabolic heartbeat of the cell. When glucose or fatty acids are catabolized in the mitochondria, NAD+ accepts electrons and protons, becoming NADH. That NADH then feeds the electron transport chain, driving ATP synthesis through oxidative phosphorylation. Without adequate NAD+, this entire electron relay stalls.

Redox Cycling and Energy Production

In glycolysis, two molecules of NAD+ are reduced to NADH for each glucose molecule processed. In the Krebs cycle (also called the citric acid cycle), three more NADH molecules are generated per acetyl-CoA turn. The net result: the ratio of NAD+ to NADH — the "redox potential" — directly sets the rate at which cells can generate ATP. Lower NAD+ means a lower NAD+/NADH ratio, which impairs mitochondrial efficiency and shifts metabolism toward less efficient anaerobic pathways. This is one mechanistic reason older adults often report reduced energy and exercise tolerance.

Beyond Redox: NAD+ as a Signaling Molecule

NAD+ is also consumed — not just temporarily reduced — in three major enzymatic families. Sirtuins (SIRTs 1–7) use NAD+ to cleave acetyl groups from lysine residues on histones and proteins, releasing nicotinamide and O-acetyl-ADP-ribose as byproducts. PARPs (poly-ADP-ribose polymerases) consume NAD+ to build poly-ADP-ribose chains on damaged chromatin, flagging breaks for repair. CD38 ectoenzymes hydrolyze NAD+ as part of calcium signaling. Crucially, all three reactions destroy NAD+ rather than recycle it, so total cellular NAD+ levels depend on a continuous biosynthetic replenishment.

The Salvage Pathway and Biosynthesis

Cells primarily regenerate NAD+ through the salvage pathway: nicotinamide (NAM), released when sirtuins and PARPs cleave NAD+, is recycled back into NMN (nicotinamide mononucleotide) by the rate-limiting enzyme NAMPT, then converted to NAD+ by NMNAT enzymes. A secondary de novo pathway synthesizes NAD+ from tryptophan via kynurenine intermediates — a slow, multi-step route that becomes more important as salvage capacity falls with age.

Why NAD+ Declines With Age — CD38, PARP, NAMPT, and Tryptophan Competition

The 50% drop in tissue NAD+ between early adulthood and late middle age is not caused by a single mechanism. It is the compounding result of at least four converging processes.

1. CD38 Inflammaging

CD38 is an ectoenzyme with extraordinarily high NAD+ hydrolase activity — far more efficient at consuming NAD+ than sirtuins or PARPs. In young tissue, CD38 expression is modest. But chronic low-grade inflammation (inflammaging) that accumulates with age dramatically upregulates CD38 in macrophages and other immune cells. Research from Johan Auwerx's lab at EPFL and Vera Gorbunova's group at Rochester has demonstrated that CD38 is the dominant driver of the age-related NAD+ decline in tissues like liver and muscle. Notably, the flavonoid apigenin and the drug 78c (a potent CD38 inhibitor) raise NAD+ in aged mice, independently of precursor supplementation.

2. PARP Activation from Accumulated DNA Damage

PARP1 is the cell's first-responder to DNA strand breaks. It binds damaged DNA within seconds and synthesizes branching poly-ADP-ribose (PAR) chains, consuming 100–200 NAD+ molecules per DNA break event. As cells age and accumulate more oxidative and replicative DNA damage, PARP1 activity increases chronically — draining NAD+ reserves faster than the salvage pathway can replenish them. This creates a feedback trap: low NAD+ impairs sirtuin-dependent genome maintenance, increasing DNA damage, which triggers more PARP activity, further depleting NAD+.

3. NAMPT Rate-Limiting Enzyme Decline

NAMPT (nicotinamide phosphoribosyltransferase) is the bottleneck of the salvage pathway. It converts nicotinamide into NMN using phosphoribosyl pyrophosphate (PRPP). NAMPT expression falls with age in multiple tissues, measured both at the mRNA and protein level. The result is a reduced capacity to recycle nicotinamide back into the NAD+ pool, even when substrate is available. This is the key theoretical rationale for NMN supplementation: bypassing the NAMPT step by supplying NMN directly.

4. Tryptophan Competition via the Kynurenine Pathway

Roughly 60 mg of tryptophan is theoretically required to synthesize 1 mg of niacin-equivalent NAD+ through the de novo Preiss-Handler pathway. With aging, chronic inflammation upregulates indoleamine 2,3-dioxygenase (IDO), shunting tryptophan toward immune-activating kynurenines rather than toward NAD+ synthesis. This means the backup de novo NAD+ biosynthesis route becomes simultaneously more relied upon and less efficient — a double disadvantage in older adults with low-grade systemic inflammation.

The Sirtuin/PARP Connection — SIRT1, SIRT3, SIRT6, and the NAD+ Competition

Understanding the sirtuin-PARP dynamic is critical because it reveals why NAD+ depletion produces such broad biological deterioration — and why simply restoring NAD+ may not be sufficient if DNA damage is already extreme.

SIRT1: Metabolic and Epigenetic Master Switch

SIRT1 is the most studied sirtuin. It deacetylates histones H3 and H4 to silence inflammatory gene programs, activates PGC-1α to drive mitochondrial biogenesis, and suppresses NF-κB — the master regulator of the inflammatory response. SIRT1 activity is directly proportional to available NAD+. When NAD+ falls in aging cells, SIRT1 activity collapses, gene silencing deteriorates, mitochondria fail to replicate, and inflammatory signaling escalates. Caloric restriction extends lifespan partly by raising the NAD+/NADH ratio, thereby activating SIRT1.

SIRT3: Mitochondrial Protein Quality Control

SIRT3 is the primary mitochondrial sirtuin. It deacetylates and activates enzymes in the electron transport chain, the Krebs cycle, and the antioxidant network (notably MnSOD). In aged mice, SIRT3 knockout accelerates hearing loss, liver steatosis, and metabolic syndrome — phenotypes reversed by NAD+ repletion. In humans, SIRT3 polymorphisms correlate with exceptional longevity in multiple cohort studies.

SIRT6: Genomic Stability and Telomere Maintenance

SIRT6 deacetylates histone H3K9 and H3K56 at sites of DNA double-strand breaks, facilitating recruitment of repair factors. SIRT6 also suppresses the retrotransposons (mobile DNA elements) that become active in aged cells and contribute to genomic instability. Mice overexpressing SIRT6 live ~15% longer; SIRT6 knockout mice age at an accelerated rate with severe metabolic defects. Because SIRT6 is a major NAD+ consumer concentrated at telomeric chromatin, declining NAD+ selectively impairs SIRT6 function and telomere maintenance.

PARP1 — Necessary Adversary

PARP1 is not an enemy; it is a survival enzyme. Without PARP1, cells accumulate lethal DNA damage. But because PARP1 and sirtuins compete for the same NAD+ pool — and PARP1 has higher affinity for NAD+ under conditions of DNA stress — activated PARP1 effectively silences sirtuin activity. David Sinclair's group at Harvard framed this as a "competition hypothesis": the age-related increase in DNA damage chronically activates PARP1, outcompeting sirtuins for NAD+ and accelerating epigenetic deterioration. NAD+ supplementation raises the pool size, allowing both systems to operate simultaneously rather than one crowding out the other.

Precursor Comparison — NMN vs NR, CD73, NRK Pathways, and the Brenner/Guarente Debate

The commercial landscape of NAD+ precursors is dominated by two molecules: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are converted to NAD+ in cells, but via distinct enzymatic routes — and this distinction matters for tissue targeting and clinical expectations.

Nicotinamide Riboside (NR) — The NRK Pathway

NR is a nucleoside form of vitamin B3 first characterized as an NAD+ precursor by Charles Brenner (then at Dartmouth) in 2004. Cells take up NR via specific nucleoside transporters (SLC29 family), then phosphorylate it to NMN using NRK1 or NRK2 (nicotinamide riboside kinases). NMN is then converted to NAD+ by NMNAT enzymes. Critically, NR does not require NAMPT — making it a true bypass route around the salvage pathway's rate-limiting step. Brenner argues that NR's safety profile is well-established through its natural presence in cow's milk, and multiple phase I/II trials have confirmed its bioavailability and tolerability in humans.

Nicotinamide Mononucleotide (NMN) — The CD73 Controversy

NMN is one step further down the salvage pathway than NR — it is already phosphorylated. Early mouse research by Shin-ichiro Imai at Washington University showed dramatic benefits of NMN injections in aged mice. But the question of how NMN enters cells became contentious. In 2019, Imai's group identified Slc12a8 as a potential NMN transporter in mouse intestine, suggesting NMN can enter cells intact. However, independent researchers — including Brenner — demonstrated that circulating NMN must first be dephosphorylated to NR by the ecto-5'-nucleotidase CD73 before cell entry. This would mean NMN supplementation ultimately works via NR anyway, and the extra phosphate group provides no advantage. The debate remains unresolved, with some human pharmacokinetic data (Trammell et al. 2016) showing NMN-specific blood metabolites. Practically, both compounds appear to raise blood and tissue NAD+ in human trials — the mechanistic dispute does not negate the clinical question.

Lachlan Brenner vs. David Guarente — The Scientific Divide

Charles Brenner (NR) and David Sinclair/Leonard Guarente (NMN advocates) have represented distinct scientific camps. Brenner has consistently argued that human data for NR are more robust and mechanistically cleaner. Guarente's company (Elysium Health) markets an NR product, while Sinclair's research has often highlighted NMN. Neither camp has produced a definitive head-to-head human RCT comparing NR and NMN on hard clinical endpoints — such a trial remains a gap in the literature. Pharmacokinetic studies suggest both raise whole-blood NAD+ equivalently at similar molar doses.

Practical Tissue Considerations

NRK1 is highly expressed in liver and red blood cells but relatively low in skeletal muscle. NRK2, by contrast, is highly expressed in heart and skeletal muscle. This differential expression may partly explain why different tissues respond to NR versus NMN differently. The Yoshino 2021 trial specifically measured skeletal muscle NAD+ after NMN supplementation combined with exercise — a tissue where the NRK2 pathway is active. Future trials stratifying by tissue type will clarify whether specific precursors should be targeted to specific pathologies.

Human Clinical Trials — Yoshino 2021, NADPARK, Pencina 2023, Dollerup 2018

Animal data on NAD+ precursors are extensive and impressive. The critical question is whether these findings translate to humans. The following trials represent the strongest human evidence to date.

Yoshino et al. 2021 — NMN + Exercise in Postmenopausal Women (Science)

Published in Science, this randomized, double-blind, placebo-controlled trial enrolled 25 postmenopausal women with prediabetes or overweight. Participants received NMN 250 mg/day for 10 weeks while following a structured exercise program. The NMN group showed significant increases in skeletal muscle NAD+ (confirmed by 31P-MRS), improved insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, and upregulation of genes involved in muscle remodeling and mitochondrial function. Importantly, this was not a simple supplement trial — the exercise-NMN interaction appeared to be required for the metabolic benefits. The NMN alone arm was not powered to isolate effects without exercise.

NADPARK Trial — NR in Parkinson's Disease Brain (Cell Metabolism, 2022)

Brakedal et al. designed this phase I/II trial specifically to measure NAD+ in the brain — a tissue previously inaccessible to supplementation studies — using 31P-MRS (phosphorus magnetic resonance spectroscopy). Participants with early Parkinson's disease received NR 1000 mg/day or placebo for 12 weeks. The NR group showed a statistically significant 25% increase in brain NAD+ levels, along with proteomics evidence of improved mitochondrial function in cerebrospinal fluid. This is the first human trial to directly confirm that oral NR supplementation crosses the blood-brain barrier and raises CNS NAD+ — a landmark finding for neurodegenerative disease research.

Pencina et al. 2023 — NMN and Testosterone in Older Men (J Clin Endocrinol Metab)

This 12-week RCT enrolled 32 men aged 65 and older and tested NMN 1000 mg/day versus placebo. Beyond measuring blood NAD+, the trial examined testosterone levels — an intriguing endpoint given sirtuin involvement in steroidogenesis. NMN significantly raised whole-blood NAD+ and was associated with modest but significant increases in bioavailable testosterone. The mechanism hypothesized involves SIRT1 activation in Leydig cells improving steroidogenic enzyme activity. The trial was small and the testosterone finding requires replication in a larger cohort.

Dollerup et al. 2018 — NR Safety and Metabolic Effects (Nat Commun)

This was one of the first rigorous human RCTs of an NAD+ precursor in a metabolically relevant population. Twelve weeks of NR 1000 mg/day in obese men was safe and well-tolerated, significantly raised whole-blood NAD+ by ~60%, but produced no significant changes in insulin sensitivity, body composition, or hepatic lipid content. This "null result" was valuable: it established NR's safety ceiling and suggested that NAD+ repletion alone — without exercise or in the context of obesity — may be insufficient to produce metabolic improvements. It also underscored that blood NAD+ is not a complete proxy for tissue or mitochondrial NAD+ changes.

Summary of Key Human Trials

Recommended Supplements

The following products are selected based on the dose ranges used in published human clinical trials. These are affiliate links — purchasing through them supports LongevityLab at no additional cost to you.

What the Evidence Does and Does Not Show

The human data on NAD+ precursors is compelling and rapidly maturing — but it does not yet show extended human lifespan, reversal of diagnosed disease, or reliable replacement for lifestyle fundamentals. What the evidence does demonstrate is that oral NMN and NR safely and substantially raise blood and tissue NAD+ in humans; that at least in specific contexts (skeletal muscle with exercise, brain in Parkinson's patients) those elevated NAD+ levels correlate with measurable functional improvements; and that the mechanistic rationale connecting NAD+ to sirtuin activity, DNA repair, and mitochondrial function is extremely well-supported by basic science.

The honest framing is this: if you are in your forties or fifties, engage in regular exercise, maintain a low-inflammatory diet, and sleep adequately, NAD+ precursor supplementation at trial-validated doses represents a well-tolerated, biologically plausible intervention with a reasonable evidence base. If you are sedentary, sleep-deprived, or chronically inflamed, no supplement will compensate for those deficits. The protocol above reflects that priority ordering.